Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib

Table 2 Univariate Cox proportional hazards regression analysis for overall survival

Factor	HR (95%CI)	P value
Sex (Male/Female)	1/0.723 (0.314-1.666)	0.446
Age (< 60/≥ 60 yr)	1/1.233 (0.698-2.179)	0.470
α-fetoprotein (< 400/≥ 400 ng/mL)	1/1.279 (0.821-1.995)	0.277
ECOG performance (0/1)	1/1.058 (0.645-1.735)	0.824
Hepatitis B (No/Yes)	1/2.665 (0.653-10.874)	0.172
Previous TACE (No/Yes)	1/2.997 (1.831-4.903)	< 0.001
Ascites (Absent/ Present)	1/1.440 (0.922-2.250)	0.109
Child-Pugh classification (A/B)	1/1.342 (0.751-2.400)	0.321
PVTT (Absent/ Present)	1/2.678 (1.697-4.227)	< 0.001
Absent	1.000
Main PVTT	19.206 (8.436-43.727)	< 0.001
Branch PVTT	2.246 (1.386-3.639)	0.001
Extrahepatic metastasis (No/Yes)	1/1.910 (1.182-3.087)	0.008
Number of tumor (1/≥ 2)	1/1.125 (0.620-2.043)	0.698
Maximum tumor diameter (≤ 3/> 3 cm)	1/1.029 (0.472-2.244)	0.944
Early disease control (No/Yes)	1/0.362 (0.227-0.577)	< 0.001